Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of asthma~* History of asthma medication use during the 2005 fall ragweed season~* Suspected ragweed allergy~* Positive laboratory tests for ragweed allergy~Exclusion Criteria:~* Received immunotherapy for ragweed or other allergens within the 5 years prior to study entry~* Received anti-IgE (omalizumab) within the year prior to study entry~* 3 or more courses of oral corticosteroids for asthma within the year prior to study entry~* Inpatient hospitalization for asthma within the 5 years prior to study entry~* History of respiratory failure or intubation for asthma~* Smoking within the 6 months prior to study entry~* Greater than 5 pack/year history of smoking~* Clinically significant acute or chronic illness~* Chronic immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).